You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
亞洲雜貨(08413.HK)斥12億元購幹細胞生物技術公司
阿思達克 04-27 10:31
亞洲雜貨(08413.HK)公布,斥12億元收購「卡替(上海)生物技術」,其中6.28億元會透過配售股份償付,5.72億元會透過發行承兌票據償付。收購對象是指重組完成後透過收購卡替的全部已發行股本,及合約安排對卡替生物技術的財務及運營管理及業績,以及卡替生物技術營運所得的所有經濟利益有實際控制權。

卡替生物技術從事幹細胞相關領域生物工程、醫藥研發及其他相關健康管理服務;及於中國用於搶救及製備方法的藥物組合物的專利許可。

亞洲雜貨表示,儘管公司將大部分精力用於發展其現有業務,惟收購事項為多元化集團業務組合及迎合具有較高進入門檻的小眾行業的絕佳機會。

另外,待收購事項完成後,公司須合共配發及發行31.4億股新股份。董事會建議透過增設額外80億股新股份,將公司法定股本由200萬元,分為20億股股份,增加至10億元,分為100億股。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account